Kiniksa's ARCALYST Soars, Fueling a Next-Gen Cardiovascular Pipeline

LONDON, UK – April 28, 2026 – Kiniksa Pharmaceuticals today announced stellar first-quarter financial results, underscoring the powerful commercial momentum of its flagship drug, ARCALYST. The therapy for recurrent pericarditis saw net product revenue surge 56% year-over-year to $214.3 million, prompting the company to significantly raise its full-year 2026 revenue forecast to between $930 million and $945 million. This commercial success is not just bolstering the company's bottom line; it's funding a strategic push to redefine treatment for the debilitating cardiovascular condition with a pipeline of next-generation therapies.

The Anatomy of a Blockbuster Success

The remarkable growth of ARCALYST is a case study in successful rare disease commercialization. Five years after its launch, the drug, which blocks IL-1 alpha and beta signaling, continues to expand its footprint as the only FDA-approved treatment for recurrent pericarditis. The first-quarter performance was driven by what the company describes as broad and expanding adoption, with growth observed in both new and repeat prescribers.

Since its launch, more than 4,550 physicians have prescribed ARCALYST, a clear indicator of growing confidence within the cardiology and rheumatology communities. This confidence is translating into longer-term use, with the average duration of therapy now approaching three years—a timeline that aligns with the median duration of the chronic inflammatory disease itself. This sustained use not only points to the drug's efficacy in managing a difficult-to-treat condition but also provides a stable and predictable revenue stream for Kiniksa.

"Five years from launch, Kiniksa continues to deliver strong ARCALYST revenue growth, driven by expanding adoption of IL-1α and IL-1β inhibition for recurrent pericarditis," said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa, in a statement. "As the first quarter progressed, growth was observed in both new and repeat prescribers, providing momentum for our ARCALYST franchise for the rest of the year."

The addressable market for recurrent pericarditis in the U.S. is estimated at approximately 40,000 patients annually, with about 14,000 experiencing multiple recurrences. With market penetration still in the early stages, Kiniksa has significant room for growth as it works to establish ARCALYST as a standard of care, moving it earlier in the treatment paradigm for a condition traditionally managed with NSAIDs, colchicine, and corticosteroids.

Innovating from Within: Building a Pericarditis Powerhouse

While ARCALYST's performance is impressive, Kiniksa is not resting on its laurels. The company is leveraging its commercial success to build a dominant franchise in recurrent pericarditis by developing its own next-generation therapies designed to improve upon its current blockbuster. The strategy hinges on enhancing patient convenience, a critical factor in managing chronic diseases.

At the forefront of this effort is KPL-387, an investigational monoclonal antibody that also inhibits IL-1 signaling. Its key differentiator is a formulation designed for a single monthly subcutaneous self-injection. This would represent a significant quality-of-life improvement over ARCALYST's weekly dosing schedule, potentially improving adherence and reducing the treatment burden for patients. Kiniksa announced that data from the Phase 2 portion of its clinical trial are expected in the second half of 2026, with plans to initiate a pivotal Phase 3 trial by the end of the year.

Behind KPL-387 is KPL-1161, an even more ambitious project. This Fc-modified antibody is engineered for an extended half-life with the target profile of a quarterly subcutaneous injection. If successful, a once-per-quarter treatment could fundamentally alter the management of recurrent pericarditis. Kiniksa is advancing KPL-1161 through preclinical development and expects to initiate a first-in-human Phase 1 trial by year-end.

This two-pronged pipeline strategy demonstrates a forward-thinking approach to life-cycle management. By developing superior follow-on products internally, Kiniksa aims to preempt potential competitors and seamlessly transition patients to its own improved therapies, thereby protecting and expanding its market leadership for the long term.

A Fortress Balance Sheet Funding Future Growth

The financial engine of ARCALYST has transformed Kiniksa into a profitable, self-sustaining biopharmaceutical company with a formidable balance sheet. The company reported a net income of $22.6 million for the first quarter, a 166% increase from the $8.5 million reported in the same period last year.

More importantly, Kiniksa ended the quarter with $468.1 million in cash and investments and no debt. This robust financial position provides the company with the flexibility and resources to aggressively fund its clinical pipeline without relying on external financing or diluting shareholder value. Operating expenses rose in the quarter, driven by investments in both the commercialization of ARCALYST and the clinical and manufacturing activities for the KPL-387 program—a clear sign that profits from the present are being strategically reinvested into the future.

This financial independence is a significant competitive advantage. It also sets the stage for even greater profitability down the road. While Kiniksa shares a portion of ARCALYST's profits with Regeneron, which discovered the drug, the pipeline assets KPL-387 and KPL-1161 are independently developed. This means Kiniksa stands to retain 100% of the economics from these future products, a move that would dramatically improve the company's gross margins and long-term value proposition.

Kiniksa’s journey illustrates a clear blueprint for biotech success: identify a disease with high unmet need, successfully launch a first-in-class therapy, and then use that commercial strength to build a durable, multi-generational franchise. With a blockbuster drug still on an upward trajectory and a promising pipeline aimed at setting a new standard of care, the company has solidified its position as a leader in cardiovascular rare disease and is poised for sustained growth in the years ahead.